These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23630281)

  • 21. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer.
    Zhang L; Mu C; Zhang T; Wang Y; Wang Y; Fan L; Liu C; Chen H; Shen J; Wei K; Li H
    ACS Appl Mater Interfaces; 2020 Jul; 12(29):32360-32371. PubMed ID: 32613835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
    Ritter CA; Perez-Torres M; Rinehart C; Guix M; Dugger T; Engelman JA; Arteaga CL
    Clin Cancer Res; 2007 Aug; 13(16):4909-19. PubMed ID: 17699871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy.
    Tan Y; Peng Y; Ai L; Li Y; Qu YX; Wang D; Su Y; Deng T; Fu T; Zhao Z; Wang XQ; Tan W
    Bioconjug Chem; 2020 Jul; 31(7):1766-1774. PubMed ID: 32463664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor targeting by an aptamer.
    Hicke BJ; Stephens AW; Gould T; Chang YF; Lynott CK; Heil J; Borkowski S; Hilger CS; Cook G; Warren S; Schmidt PG
    J Nucl Med; 2006 Apr; 47(4):668-78. PubMed ID: 16595502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer.
    Ruan J; Song H; Qian Q; Li C; Wang K; Bao C; Cui D
    Biomaterials; 2012 Oct; 33(29):7093-102. PubMed ID: 22796163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.
    Liu Z; Duan JH; Song YM; Ma J; Wang FD; Lu X; Yang XD
    J Transl Med; 2012 Jul; 10():148. PubMed ID: 22817844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
    Yang Z; Barnes CJ; Kumar R
    Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
    Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
    Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
    Cui Y; Li SB; Peng XC; Wu J; Fu GH
    Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
    Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted therapy against HER2
    Tang Z; Jun Y; Lv Y; Li Y; Zhang Z; Tao M; Chen X; He J; Zhang L; Wang QL
    J Drug Target; 2020 Feb; 28(2):186-194. PubMed ID: 31134823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
    Yang Z; Luo H; Cao Z; Chen Y; Gao J; Li Y; Jiang Q; Xu R; Liu J
    Nanoscale; 2016 Jun; 8(22):11543-58. PubMed ID: 27203688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.
    Esposito CL; Passaro D; Longobardo I; Condorelli G; Marotta P; Affuso A; de Franciscis V; Cerchia L
    PLoS One; 2011; 6(9):e24071. PubMed ID: 21915281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.
    Paris L; Cecchetti S; Spadaro F; Abalsamo L; Lugini L; Pisanu ME; Iorio E; Natali PG; Ramoni C; Podo F
    Breast Cancer Res; 2010; 12(3):R27. PubMed ID: 20462431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of cell proliferation by an anti-EGFR aptamer.
    Li N; Nguyen HH; Byrom M; Ellington AD
    PLoS One; 2011; 6(6):e20299. PubMed ID: 21687663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody).
    Kim HJ; Sung HJ; Lee YM; Choi SI; Kim YH; Heo K; Kim IH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32384770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.